Αποτελέσματα Αναζήτησης
The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in...
- FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
Today, the U.S. Food and Drug Administration approved...
- FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
1 Απρ 2016 · Several long-term treatments can help people overcome opioid addiction. One of them, naltrexone, may help people who have trouble sticking with taking a pill every day. Naltrexone can be offered as a monthly injection called Vivitrol, which has been shown to help more people stay on treatment as compared to ...
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder...
This guideline provides a framework for how to build a clinical practice of injectable opioid agonist treatment and recommends that this treatment should be considered for individuals with severe, treatment-refractory opioid use disorder and ongoing illicit injection opioid use.
19 Φεβ 2019 · A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly extended-release injection.
INDICATION: SUBLOCADE ® (buprenorphine extended-release) injection, for subcutaneous use (CIII) is for adults with moderate to severe opioid addiction whose withdrawal symptoms are controlled by oral buprenorphine for at least 7 days.
Society (better said the government) needs to invest in treating addiction adequately, especially in OUD, where we actually have treatments that have been proven to work. New providers must be targeted to provide long-acting injectables.
